# Safety and Efficacy of DA-9805 for Parkinson's Disease

> **NCT03189563** · PHASE2 · COMPLETED · sponsor: **Dong-A ST Co., Ltd.** · enrollment: 61 (actual)

## Conditions studied

- Parkinson's Disease

## Interventions

- **DRUG:** DA-9805 45mg
- **DRUG:** DA-9805 90mg
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03189563
- **Lead sponsor:** Dong-A ST Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-02-06
- **Primary completion:** 2019-04-10
- **Final completion:** 2019-04-10
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2022-05-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03189563

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03189563, "Safety and Efficacy of DA-9805 for Parkinson's Disease". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03189563. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*